Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Avistone of Beijing Raises $200 Million; Will Combine with Pearl Biotech

publication date: Dec 8, 2021

Beijing Avistone Pharma, a precision oncology company, received a more than $200 million strategic investment led by Vivo Capital. The capital will support the combination of Avistone and Pearl Biotech, which is also based in Beijing. The two companies plan to create a fully-integrated targeted oncology platform. Avistone's lead drug is a c-Met inhibitor in late-stage clinical development for genetically-defined patients with non-small cell lung cancer and glioblastoma. Bain Capital and Primavera Capital also participated in the investment. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital